895367-63-2

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-N-(2-FLUOROBENZYL)ACETAMIDE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs with diverse therapeutic purposes. Its unique chemical structure allows it to be a valuable component in the creation of innovative medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 2-CHLORO-N-(2-FLUOROBENZYL)ACETAMIDE serves as an intermediate in the synthesis of agrochemicals, potentially enhancing crop protection and management through the development of new chemical agents.
Used in Research and Development:
2-CHLORO-N-(2-FLUOROBENZYL)ACETAMIDE is utilized in research and development settings for the production of new chemical compounds, exploring its potential applications and properties to advance scientific understanding and innovation in chemistry and related fields.
Due to its chemical structure and properties, it is crucial to handle 2-CHLORO-N-(2-FLUOROBENZYL)ACETAMIDE with care and adhere to safety guidelines to ensure the safety of individuals and the environment.

InChI:InChI=1/C9H9ClFNO/c10-5-9(13)12-6-7-3-1-2-4-8(7)11/h1-4H,5-6H2,(H,12,13)

Upstream product

• 89-99-6 2-fluorobenzylamine 
• 79-04-9 chloroacetyl chloride 

Relevant academic research and scientific papers

Lanthanide Complexes that Respond to Changes in Cyanide Concentration in Water

Cyanide ions are shown to interact with lanthanide complexes of phenacylDO3A derivatives in aqueous solution, giving rise to changes in the luminescence and NMR spectra. These changes are the consequence of cyanohydrin formation, which is favored by the c

4-aminoacylphenoxyacetamide compound and medicine uses thereof

The invention belongs to the field of pharmaceutical chemistry, and relates to 4-aminoacylphenoxyacetamide compound shown as an I formula and medicine uses thereof, and in the formula, G, Z, R, m and n are described in the specification in detail. The compounds are capable of inhibiting sphingomyelin synthase activity, and are applicable to treat diseases caused by abnormal increase of sphingomyelin level. The invention further comprises compounds shown as the formula I structure, pharmaceutically-acceptable salts thereof, and application of pharmaceutical composition taking the compounds or salts thereof as an effective active composition to prevent and treat diseases caused by abnormal increase of sphingomyelin level. The diseases caused by abnormal increase of sphingomyelin level comprise atherosclerosis, fatty liver, obesity, II type diabetes and other metabolic syndrome.

Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor

The M4 mAChR is implicated in several CNS disorders and possesses an allosteric binding site for which ligands modulating the affinity and/or efficacy of ACh may be exploited for selective receptor targeting. We report the synthesis of a focused library of putative M4 PAMs derived from VU0152100 and VU10005. These compounds investigate the pharmacological effects of previously identified methoxy and fluoro substituents, providing useful estimates of affinity (KB), cooperativity (αβ), and direct agonist properties (τB).

SUBSTITUTED HETEROCYCLIC COMPOUNDS

Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.